Last updated: February 13, 2026
What Is the Market Status for NDC 00527-1396?
NDC 00527-1396 is associated with the drug Xyrem (Sodium oxybate), licensed for the treatment of narcolepsy with cataplexy and controls excessive daytime sleepiness. This medication is marketed by Boston Pharmaceuticals and Jazz Pharmaceuticals. Its market presence remains significant due to the limited treatment options for narcolepsy.
How Is the Market Currently Structured?
- Market Size: The global narcolepsy market was valued at approximately $220 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 5-6% through 2027. The U.S. accounts for nearly 75% of the market, driven by strict regulation and high diagnosis rates.
- Key Competitors: The principal competitor is Xyrem (Jazz Pharmaceuticals), which dominates with a market share exceeding 90% due to patent protections and a well-established distribution network. Other drugs, such as sodium oxybate formulations from generics and off-label uses, hold minor shares.
What Are the Price Projections for NDC 00527-1396?
- Current Pricing: The average wholesale price (AWP) for Xyrem is approximately $32,000 per year per patient, with a typical dosing regimen of 4.5 grams nightly divided into two doses. Insurance coverage, rebates, and patient assistance programs affect actual costs.
- Projected Trends: With patent expirations approaching or recent generic entries in some markets, price reductions of 20-30% are expected over the next 2-3 years in the U.S. market. Genric sodium oxybate formulations could see prices drop to approximately $20,000 annually.
- Impact of Regulatory Changes: The FDA's ongoing scrutiny of controlled substances may influence pricing and reimbursement practices. Market shifts toward alternative therapies could curtail revenue growth, especially if new devices or drugs enter the market.
How Do Patent and Regulatory Factors Influence Market Dynamics?
- Patent Protections: Xyrem's patents extend until 2024-2025, preventing generic competition. Once expired, generics can enter, pressuring prices and market share.
- Regulatory Environment: The DEA's scheduling of sodium oxybate as a Schedule III or Schedule II drug influences prescribing practices and insurance reimbursement.
- Off-Label Use and Abuse Potential: The drug's potential for abuse affects prescribing restrictions and monitoring costs, impacting overall market size.
What Are Future Opportunities and Challenges?
- Opportunities: Development of formulations with improved safety profiles, such as extended-release versions, could capture niche markets.
- Challenges: Increasing regulation, the emergence of novel therapies for narcolepsy, and potential safety concerns could limit growth.
Key Market Data Summary Table
| Parameter |
Value / Projection |
| Global market size (2022) |
$220 million |
| CAGR (2023-2027) |
5-6% |
| U.S. market share |
~75% |
| Price (current annual) |
~$32,000 |
| Expected generic entry |
2024-2025 |
| Predicted generic price |
~$20,000/year |
| Patent expiration |
2024-2025 |
Key Takeaways
- NDC 00527-1396 (Xyrem) dominates the narcolepsy market, with high revenue driven by limited competitors.
- Prices are expected to decline substantially after patent expiration, influenced by generic entry and competitive pressures.
- The size of the market remains steady, supported by increasing diagnosis and awareness, but growth may slow due to regulatory and safety concerns.
- Insurance coverage heavily influences actual patient costs, impacting market penetration.
- Future innovations could shift market dynamics, but current trends favor falling prices and market consolidation.
FAQs
1. When will generic versions of NDC 00527-1396 become available?
Generic sodium oxybate formulations are likely to enter the market around 2024-2025, following the expiration of key patents.
2. How does regulation impact the pricing of sodium oxybate?
Regulatory classification as a Schedule III or II drug affects prescribing practices, insurance coverage, and monitoring costs, which can influence prices and access.
3. What are key factors driving market growth?
Increasing diagnosis rates of narcolepsy, improved management strategies, and new formulations contribute to steady market expansion.
4. Are there alternative therapies impacting this market?
Yes, medications like amphetamine-based stimulants and other wakefulness-promoting agents are used off-label, but none match xanax's approved indication.
5. How do safety concerns influence market prospects?
Potential abuse and safety issues lead to more stringent regulations, which can limit prescribing and slow market growth.
References
- IBISWorld. Narcolepsy Market Research Report 2022.
- MarketWatch. "Global narcolepsy therapeutics market forecast," 2022.
- FDA. Drug Approval and Regulatory Guidelines, 2022.
- IQVIA. U.S. Pharmaceutical Market Trends, 2023.
- Boston Pharmaceuticals. NDC information and product profiles.
